These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1380 related items for PubMed ID: 19202451

  • 1. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V.
    Transplantation; 2009 Feb 15; 87(3):436-44. PubMed ID: 19202451
    [Abstract] [Full Text] [Related]

  • 2. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T, Jindra P, Svecová M, Kormunda S, Opatrný K, Treska V.
    J Clin Virol; 2006 Jun 15; 36(2):146-51. PubMed ID: 16531113
    [Abstract] [Full Text] [Related]

  • 3. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Jun 15; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 15; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 5. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation.
    Li L, Chaudhuri A, Weintraub LA, Hsieh F, Shah S, Alexander S, Salvatierra O, Sarwal MM.
    Pediatr Transplant; 2007 Mar 15; 11(2):187-95. PubMed ID: 17300499
    [Abstract] [Full Text] [Related]

  • 6. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J, Morales-Buenrostro LE, Correa-Rotter R, Muñoz-Trejo T, Zúñiga-Varga J, Cuéllar-González JV, Mayorga-Madrigal H, Vanegas-Carrero R, Aranda F, Rodríguez-Romo R, Herrera-Garcia C, González-Michaca L, Sierra-Madero JG.
    Rev Invest Clin; 2008 Mar 15; 60(5):365-74. PubMed ID: 19227433
    [Abstract] [Full Text] [Related]

  • 7. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, Angelis M, Cooper J, Barefoot L, Rohrer R, Snydman DR.
    Liver Transpl; 2005 Dec 15; 11(12):1597-602. PubMed ID: 16315314
    [Abstract] [Full Text] [Related]

  • 8. Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines.
    Dmitrienko S, Balshaw R, Machnicki G, Shapiro RJ, Keown PA.
    Transplantation; 2009 Feb 27; 87(4):570-7. PubMed ID: 19307796
    [Abstract] [Full Text] [Related]

  • 9. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.
    Dtsch Med Wochenschr; 1997 May 02; 122(18):565-71. PubMed ID: 9190308
    [Abstract] [Full Text] [Related]

  • 10. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
    Madan RP, Campbell AL, Shust GF, Kahn AR, Wistinghausen B, Posada R, Kerkar N, Shneider BL, Emre S, Herold BC.
    Transplantation; 2009 May 15; 87(9):1318-24. PubMed ID: 19424031
    [Abstract] [Full Text] [Related]

  • 11. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J, Caston-Osorio JJ, Martín C, Rivero A, Doblas A, Rojas R, Gómez P, Martínez F, Torres A.
    Enferm Infecc Microbiol Clin; 2010 Jan 15; 28(1):6-12. PubMed ID: 19409666
    [Abstract] [Full Text] [Related]

  • 12. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 15; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 13. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 14. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC.
    N Engl J Med; 1999 May 13; 340(19):1462-70. PubMed ID: 10320384
    [Abstract] [Full Text] [Related]

  • 15. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T, Opatrny K, Bouda M, Treska V, Jindra P, Svecova M.
    Transpl Int; 2002 Dec 13; 15(12):615-22. PubMed ID: 12478408
    [Abstract] [Full Text] [Related]

  • 16. Interstitial fibrosis and tubular atrophy in renal allograft protocol biopsies as a surrogate of graft survival.
    Serón D.
    Transplant Proc; 2009 Mar 13; 41(2):769-70. PubMed ID: 19328976
    [Abstract] [Full Text] [Related]

  • 17. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF, Hodson EM, Jones C, Craig JC.
    Transplantation; 2006 Jan 27; 81(2):139-45. PubMed ID: 16436954
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
    Boucher A, Lord H, Collette S, Morin M, Dandavino R.
    Transplant Proc; 2006 Dec 27; 38(10):3506-8. PubMed ID: 17175316
    [Abstract] [Full Text] [Related]

  • 19. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A, Krok K, Cohen D, Blumberg E, Bloom RD.
    Transplant Proc; 2004 Dec 27; 36(10):3019-24. PubMed ID: 15686685
    [Abstract] [Full Text] [Related]

  • 20. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
    Potena L, Holweg CT, Chin C, Luikart H, Weisshaar D, Narasimhan B, Fearon WF, Lewis DB, Cooke JP, Mocarski ES, Valantine HA.
    Transplantation; 2006 Aug 15; 82(3):398-405. PubMed ID: 16906040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.